Nicholas Piramal India Limited (Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical Healthcare company with a presence in the cardio-vascular segment, the antibiotics and respiratory segments, pain management, neuro-psychiatry and anti-diabetics segments and biotechnology. For 2005-06, NPIL's recorded a turnover of Indian Rupee ("Rs") 14,100 million and profits after tax were Rs 1,700 million.
NPIL's brands in the pharma business are Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67% of the business, while its secondary brands which include Paraxin, Flagyl and Omnatax contribute around 24% of its revenues.
NPIL came into existence in 1988 when it acquired Nicholas Laboratories from Sara Lee and in the last 15 years grown primarily on acquisitions, mergers and alliances. Some of NPIL's acquisitions include the Indian operations of Roche Products Ltd., Boehringer Mannheim India Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc India Ltd., ICI India Ltd.'s Pharma Division and Aventis' Research facilities.
NPIL has joint ventures and alliances with F. Hoffmann-La Roche Ltd., Switzerland; Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK.
With the acquisition of Pfizer's Morepeth's manufacturing site in UK, Nicholas Piramal through its wholly owned subsidiary NPIL Pharmaceuticals Limited is a custom manufacturing organization.
NPIL plans to take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan. NPIL major investments in R&D which focus on formulations development, new chemical entity research, clinical research from laboratories in India and abroad. The results till now however have not been very encouraging.
Nicholas Piramal India Ltd has announced with reference to the earlier announcement dated January 22, 2008 regarding fixing of the Record Date for the purpose of determining entitlement of the shareholders of the Company to receive equity shares of "NPIL Research and Development Ltd" (NPIL) in the ratio of 1:10 pursuant to the Scheme, that the name of "NPIL Research and Development Ltd" has been changed to "Piramal Life Sciences Ltd". A certified true copy of Fresh Certificate of Incorporation Consequent upon change of Name issued by the Ministry of Corporate Affairs.
NPIL is the flagship company of the Rs. 25,000 million (US $ 500 million) Piramal Enterprises (PEL). The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.
ELECTROTEX MOVES TO JOIN HEBERLEIN FIBER TECHNOLOGY IN WATTWIL/ ELECTROTEX REJOINT HEBERLEIN FIBER TECHNOLOGY À WATTWIL
May 01, 2005; The activities of Electrotex Inc. Oberurnen, which were taken over by Heberlein Fiber Technology Inc. on January 1st, 2004, will...
Conagra rejoint le mouvement du pauvre en glucide; tandis que le Canada risque de s'opposer aux revendications du pauvre en glucide.(En Manchette Dans Ce Numero)
Apr 01, 2004; ConAgra Foods. le conglomerat agroalimentaire base a Omaha, dans le Nebraska qui est deja repute grace a sa gamme Healthy Choice...
Circuit International Mohammed VI De Tennis (Etape De Casablanca): l'Italien Starace Rejoint l'Autrichien Thiem En Finale
Nov 01, 2013; Rabat - L'Italien Potito Starace s'est qualifie, vendredi, pour la finale du tournoi ATP de Casablanca, epreuve disputee a...